Our news
Neophore appoints Michael Shih as Chief Executive Officer
Â鶹´«Ã½ appoints Michael Shih as Chief Executive Officer • Highly experienced corporate development leader with a track record of international p…
Â鶹´«Ã½ closes oversubscribed Series B extension round with additional funding from Bristol Myers Squibb
Â鶹´«Ã½ closes oversubscribed Series B extension round with additional funding from Bristol Myers Squibb Additional funding will be used to explore…
Â鶹´«Ã½ presented preclinical data from our PMS2 program at the AACR Annual Meeting, San Diego, 5 - 10 April 2024.
The Â鶹´«Ã½ team attended the American Association for Cancer Research Annual Meeting in San Diego, 5 - 10 April 2024. In collaboration with The…
Â鶹´«Ã½ raises an additional £9.6m (USD $12.2m) Series B financing extension to further progress drug discovery pipeline
Â鶹´«Ã½ raises an additional £9.6m (USD $12.2m) Series B financing extension to further progress drug discovery pipeline • Italian investors, NE…
Other news
CEO Jeff Roix spoke to BioCentury about how Â鶹´«Ã½ Ltd is developing small molecules to inhibit DNA mismatch repair (MMR) and create a pool of…
APM Health: Interview with CEO, Jeff Roix
Scrip Emerging company profile: UK-based Â鶹´«Ã½, founded in 2017, is developing novel cancer therapies based on DNA-repair technology. The company…